USPTO serial 79366831
CADENCE
Reviewed by CopyMark Law Group
Status 654
- Filing date
- Status date
- Registration date
- —
- Examiner
- CANTOR, JILLIAN REDDING
- Law office
- TMO LAW OFFICE 137
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with CADENCE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Joseph G. Chu
Joseph G. Chu JCIP155 N Lake Avenue, Suite 800Pasadena, CA 91101United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical and veterinary use or purposes; Medical diagnostic reactants for medical and veterinary diagnosis of diseases; diagnostic preparations for medical use for sale in kit form; diagnostic preparations for medical purposes; Biological indicators for medical diagnosis, namely, for detecting and diagnosing cancer; veterinary diagnostic reagents; Diagnostic reagents in kit form for conducting molecular biology assays for medical or veterinary purposes; Diagnostic reagents for medical or veterinary purposes; Diagnostic reagents for use in diagnostic tests for medical or veterinary purposes; pharmaceutical preparations for the treatment of disorders of the metabolic system; medical diagnostic reagents for testing of body fluids; Medical diagnostic assays that test for genetic anomalies for medical use; Diagnostic preparations for medical use; Biochemical preparations for diagnostic use for detecting and diagnosing cancer; Diagnostic preparations for medical purposes; Diagnostic agents for pharmaceutical use in the medical field; Test reagents for medical diagnosis, namely, disease testing; diagnostic biomarker reagents for medical purposes; Chemical preparations for diagnostic medical purposes, namely, for detecting and diagnosing cancer; Chemical preparations for use in medical diagnostics, namely, nucleic acid analysis; Chemical preparations for detecting genetic and epigenetic predispositions for medical purposes; Medical diagnostic reagents for analysis of body fluids; Synthetic deoxyribonucleic acid and synthetic ribonucleic acid for medical use, namely, for detecting and diagnosing cancer; nucleic acid amplification reagents for medical use; all of the foregoing related to cancer screening and diagnostic tests | ACTIVE | — |
| 010 | Medical diagnostic apparatus for detecting and diagnosing cancer; Medical diagnostic instruments for analysis of body fluids; Biomedical testing apparatus for RNA, DNA and protein biomarkers testing; Medical diagnostics instruments in the nature of apparatus for testing RNA, DNA and protein biomarkers; medical instruments for infectious disease testing; Medical diagnostic testing apparatus for sale in kit form for testing RNA, DNA and protein biomarkers for diagnosing and detecting cancer; Medical diagnostic apparatus for testing RNA, DNA and protein biomarkers for diagnosing and detecting cancer; Diagnostic in-vitro diagnostic testing apparatus for medical use for diagnosing and detecting cancer; Medical diagnostic testing apparatus for use in molecular biology procedures, namely, testing DNA, RNA and protein biomarkers for diagnosing and detecting cancer; Diagnostic apparatus for blood tests for medical use; all of the foregoing related to cancer screening and diagnostic tests | ACTIVE | — |
| 044 | Medical diagnostic services, namely, testing and analysis; medical testing services relating to the diagnosis and treatment of disease; medical analysis services for the diagnosis of cancer; Medical services, namely, nucleic acid analysis for cancer diagnosis and prognosis; performing diagnosis of diseases; medical services for the diagnosis of conditions of the human body; genetic testing of animals for diagnostic or treatment purposes; medical laboratory services related to the treatment of patients; Medical advisory services in the field of oncological diseases; medical analysis for the diagnosis and treatment of persons; Medical services, namely, health risk assessment surveys; health-care services for treating and detecting cancer; genetic testing for medical purposes; Medical services, namely, nucleic acid screening for medical purposes; Medical analysis services for diagnosing and detecting cancer; medical screening; Health screening services in the field of cancer; all of the foregoing related to cancer screening and diagnostic tests | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 19, 2026 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Sep 23, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Aug 27, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Feb 26, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Jan 27, 2025 | RCSC | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED | — |
| Sep 20, 2024 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Sep 4, 2024 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Sep 4, 2024 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Apr 30, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Apr 30, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Apr 30, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Apr 26, 2024 | AMPX | PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED | — |
| Apr 26, 2024 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Apr 26, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 26, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 26, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 22, 2023 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 27, 2023 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 27, 2023 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 20, 2023 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 19, 2023 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 17, 2023 | DOCK | ASSIGNED TO EXAMINER | — |
| Apr 14, 2023 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Apr 10, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Apr 6, 2023 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |